Literature DB >> 10834532

Aberrations of chromosomes 5 and 8 as recurrent cytogenetic events in anaplastic carcinoma of the thyroid as detected by fluorescence in situ hybridisation and comparative genomic hybridisation.

L Wilkens1, D Benten, J Tchinda, G Brabant, E Pötter, H Dralle, R von Wasielewski.   

Abstract

Comparative genomic hybridisation (CGH) is a technique which identifies gains and losses of DNA sequence copy number in tumours. We used CGH to search for genetic changes in one of the most aggressive malignancies--anaplastic thyroid carcinoma (ATC). For this purpose, we analysed tumour specimens of nine ATCs and DNA of two ATC cell lines. CGH detected aberrations in 10 of 11 samples, with a mean number of gains or losses per carcinoma of 4.8 (range 0-13). Total or partial changes of chromosome 8 (n=6), including gains or losses of 8p (n=6) or 8q (n=5) were those detected most frequently. Chromosome 5p was amplified in five cases. Gains in two of three samples were found for 3q, 7p, 11q and 20q. Gains in a fewer number were seen for 1p (1 case), 1q (1), 7q (2), 9q (2), 11p (2), 12q (1), 14 (1), 15 (1), 17q (2), 18p (2), 18q (1), 20p (1), 21 (2), Xp (2) and Xq (2). Losses were less frequent than gains and observed for 1p (2 cases), 1q (1), 2p (1), 2q (2), 3p (2), 3q (1), 4q (2), 6q (1), 9p (2), 9q (1), 18p (1), 18q (1) and Y (2). Examples of analysis of tumour sections and cell lines performed by fluorescence in situ hybridisation (FISH) confirmed the gains and losses found by CGH and detected additional signals for 8q21 in tumour cells in a sample with no gains or losses normally in CGH. The results suggest that aberrations of 5p, 8p and 8q, which are rarely found in differentiated thyroid carcinoma, may play an important role in the development of ATC. Therefore, these chromosomes could harbour gene loci potentially involved in the aggressiveness of neoplastic tumours, as shown in tumours such as in this study for ATC.

Entities:  

Mesh:

Year:  2000        PMID: 10834532     DOI: 10.1007/s004280050452

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  7 in total

1.  Genome-wide appraisal of thyroid cancer progression.

Authors:  Volkert B Wreesmann; Ronald A Ghossein; Snehal G Patel; Charles P Harris; Erik A Schnaser; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Pulivarthi H Rao; Bhuvanesh Singh
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Chromosomal imbalances in carcinoma showing thymus-like elements (CASTLE).

Authors:  Lothar Veits; Gunhild Mechtersheimer; Christina Steger; Jens Freitag; Gregor Mikuz; Kurt W Schmid; Walter Hofmann; Peter Schirmacher; Arndt Hartmann; Ralf J Rieker
Journal:  Virchows Arch       Date:  2011-07-07       Impact factor: 4.064

3.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

Authors:  Iñigo Landa; Tihana Ibrahimpasic; Laura Boucai; Rileen Sinha; Jeffrey A Knauf; Ronak H Shah; Snjezana Dogan; Julio C Ricarte-Filho; Gnana P Krishnamoorthy; Bin Xu; Nikolaus Schultz; Michael F Berger; Chris Sander; Barry S Taylor; Ronald Ghossein; Ian Ganly; James A Fagin
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

Review 4.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

5.  Micronucleus frequency among Iraqi thyroid disorder patients.

Authors:  Abdul Hussein Moyet AlFaisal; Intesar Jawad Kahdoom Al-Ramahi; Ismail Abdul Redah Abdul-Hassan
Journal:  Comp Clin Path       Date:  2012-12-28

6.  Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines.

Authors:  R F Rodrigues; L Roque; T Krug; V Leite
Journal:  Br J Cancer       Date:  2007-04-03       Impact factor: 7.640

7.  Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas.

Authors:  R F Rodrigues; L Roque; J Rosa-Santos; O Cid; J Soares
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.